期刊文献+

氟-18标记的吡啶基哒螨灵类似物的合成及生物性能

Synthesis and biodistribution of ^(18)F-labeled pyridyl pyridaben analogues
下载PDF
导出
摘要 目的设计并合成一种氟-18标记的哒螨灵类似物:4-氯-2-叔丁基-5-[[6-[[4-[2-[2-[2-氟[18F]乙氧基]乙氧基]乙氧基]-1H-1,2,3-三唑-1-基]甲基]-2-吡啶基]甲氧基]-3(2H)-哒嗪酮([18F]FPTP-P3),并评价其用于心肌灌注显像的可能性。方法采用[18F]F-取代OTs前体的方法进行标记,通过稳定性研究、脂水分配系数测定、生物分布实验等手段对标记物进行评价。结果 [18F]FPTP-P3的总制备时间为70~90 min,校正后的放化产率为36±5.6%,放化纯>98%。[18F]FPTP-P3为脂溶性化合物,在水溶液中可稳定放置3 h以上。生物分布实验结果显示,[18F]FPTP-P3在小鼠心肌具有一定的初始摄取,且肝部清除较快,但其心肌滞留较差。结论 [18F]FPTP-P3不具有用于心肌显像的潜力。 Objective A fluorine-18 labeled pyridazinone derivative: 4-chloro-2-tert-butyl-5-[6-[4-[2-[2-[2-[18^F]fluroethoxy]ethoxy]ethoxy]-1H-1,2,3-triazol-1-yl]methyl]-2-pyridinyl]methoxy]-3(2H)-pyridazinone ([18^F]FPTP-P3) was designed and prepared, and its potential as a myocardial perfusion imaging agent was evaluated. Methods [18^F]FPTP-P3 was prepared by substituting tosyl of precursor with 18^F. The tracer was evaluated by stability study, octanol/water partition coefficient and biodistribution study. Results The total radio-synthesis time was 70-90 min, typical decay-corrected radiochemical yield was 36±5.6%, and the radiochemical purity (RCP) was〉98% after purification. It is a lipophilic compound, and stable in water for 3 h. The results of biodistribution study in mice showed that [18^F]FPTP-P3 had certain initial heart uptake and the clearance of liver was very fast as well. However the retention of heart uptake was not ideal.Conclusion [18^F]FPTP-P3 is not suitable for heart imaging in vivo.
出处 《首都医科大学学报》 CAS 2013年第1期11-17,共7页 Journal of Capital Medical University
基金 国家自然科学基金(20871020 81271613 21271030) 北京市自然科学基金(2092018)资助项目~~
关键词 [18F]FPTP-P3 哒螨灵 心肌摄取 生物分布 [18F]FPTP-P3 pyridaben heart uptake biodistribution
  • 相关文献

参考文献9

  • 1Mou T,Jing H,Yang W. Preparation and biodistribution of[18F]FP2OP as myocardial perfusion imaging agent for positron emission tomography[J].Bioorganic and Medicinal Chemistry Letters,2010,(03):1312-1320.
  • 2Huisman M C,Higuchi T,Reder S. Initial characterization of an 18F-labeled myocardial perfusion tracer[J].Journal of Nuclear Medicine,2008,(04):630-636.
  • 3Yu M,Bozek J,Guaraldi M. Cardiac imaging and safety evaluation of BMS747158,a novel PET myocardial perfusion imaging agent,in chronic myocardial compromised rabbits[J].Journal of Nuclear Cardiology,2010,(04):631-636.
  • 4Yu M,Guaraldi M T,Bozek J. Effects of food intake and anesthetic on cardiac imaging and uptake of BMS747158-02 in comparison with FDG[J].Journal of Nuclear Cardiology,2009,(05):763-768.
  • 5Yalamanchili P,Wexler E,Hayes M. Mechanism of uptake and retention of F-18 BMS-747 158-02 in cardiomyocytes:a novel PET myocardial imaging agent[J].Journal of Nuclear Cardiology,2007,(06):782-788.
  • 6Maddahi J,Czernin J,Lazewatsky J. Phase I,First-in-Human Study of BMS747158,a Novel 18F-Labeled tracer for myocardial perfusion PET:dosimetry,biodistribution,safety,and imaging characteristics after a single injection at rest[J].Journal of Nuclear Medicine,2011,(09):1490-1498.
  • 7Sherif H M,Nekolla S G,Saraste A. Simplified quantification of myocardial flow reserve with flurpiridaz F 18:validation with microspheres in a pig model[J].Journal of Nuclear Medicine,2011,(04):617-624.
  • 8Mou T,Zhao Z,Fang W. Synthesis and preliminary evaluation of 18F-labeled pyridaben analogues for myocardial perfusion imaging with positron emission tomography[J].The Journal of Nuclear Medicine,2012,(03):472-479.
  • 9Purohit A,Radeke H,Azure M. Synthesis and biological evaluation of pyridazinone analogues as potential cardiac positron emission tomography tracers[J].Journal of Medicinal Chemistry,2008,(10):2954-2970.doi:10.1021/jm701443n.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部